Myofascial pain syndromes in the maxillofacial area: a common but underdiagnosed cause of head and neck pain

International Journal of Oral and Maxillofacial Surgery

Volumn 37, Issue 11, 2008, Pages 975-984

  Manolopoulos, Leonidas ^a   Vlastarakos, Petros V ^a   Georgiou, Lucas ^a   Giotakis, Ioannis ^a   Loizos, Anthony ^a   Nikolopoulos, Thomas P ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

head and neck pain; maxillofacial; muscular disorders; myofascial syndromes; treatment; trigger points

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BUPIVACAINE; CLONAZEPAM; LIDOCAINE; LOCAL ANESTHETIC AGENT; PLACEBO; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON;

ACUPUNCTURE; ANALGESIA; ANAMNESIS; BEHAVIOR THERAPY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG EFFICACY; HEADACHE; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; METABOLIC DISORDER; MUSCLE FUNCTION; MUSCLE WEAKNESS; MYOFASCIAL PAIN; NECK PAIN; NUTRITIONAL DISORDER; PHYSICAL EXAMINATION; PHYSIOTHERAPY; QUALITY OF LIFE; REVIEW; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; TEMPOROMANDIBULAR JOINT DISORDER; TREATMENT OUTCOME; TRIGGER POINT;

ANALGESICS; CHRONIC DISEASE; FACIAL PAIN; HEADACHE; HEADACHE DISORDERS; HUMANS; MYOFASCIAL PAIN SYNDROMES; NECK PAIN; PHYSICAL THERAPY MODALITIES;

EID: 55249101466     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijom.2008.04.023     Document Type: Review

References (106)

1. Altan L., Bingol U., Aykac M., and Yurtkuran M. Investigation of the effect of GaAs laser therapy on cervical myofascial pain syndrome. Rheumatol Int 25 (2005) 23-27
2. Alvarez D.J., and Rockwell P.G. Trigger points. diagnosis and management. Am Fam Physician 65 (2002) 653-660
3. Ariji Y., Sakuma S., Izumi M., Sasaki J., Kurita K., Ogi N., Nojiri M., Nakagawa M., Takenaka M., Katsuse S., and Ariji E. Ultrasonographic features of the masseter muscle in female patients with temporomandibular disorder associated with myofascial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98 (2004) 337-341
4. Audette J.F., Wang F., and Smith H. Bilateral activation of motor unit potentials with unilateral needle stimulation of active myofascial trigger points. Am J Phys Med Rehabil 83 (2004) 368-374 quiz 375-7, 389
5. Benecke R., Dressler D., Kunesch E., and Probst T. The introduction of botulinum toxin in the therapy of muscular pain [in German]. Schmerz 17 (2003) 450-458
6. Bengtsson A., Henriksson K.G., and Larsson J. Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 29 (1986) 817-821
7. Bogart R.K., McDaniel R.J., Dunn W.J., Hunter C., Peterson A.L., and Wright E.F. Efficacy of group cognitive behavior therapy for the treatment of masticatory myofascial pain. Mil Med 172 (2007) 169-174
8. Borodic G.E., Acquadro M., and Johnson E.A. Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert Opin Investig Drugs 10 (2001) 1531-1544
9. Buskila D. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 13 (2001) 117-127
10. Butler D.S. The Sensitive Nervous System (2000), Noigroup Publications, Adelaide, Australia
11. Cheshire W.P., Abashian S.W., and Mann J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59 (1994) 65-69
12. Dalpiaz A.S., and Dodds T.A. Myofascial pain response to topical lidocaine patch therapy: case report. J Pain Palliative Care Pharmacother 16 (2001) 99-104
13. Dalpiaz A.S., Lordon S.P., and Lipman A.G. Topical lidocaine patch therapy for myofascial pain. J Pain Palliative Care Pharmacother 18 (2004) 15-34
14. De Andres J., Cerda-Olmedo G., Valia J.C., Monsalve V., Lopez-Alarcon, and Minguez A. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain 19 (2003) 269-275
15. De Laat A., Stappaerts K., and Papy S. Counseling and physical therapy as treatment for myofascial pain of the masticatory system. J Orofac Pain 17 (2003) 42-49
16. Donaldson C.C., Nelson D.V., and Schulz R. Disinhibition in the gamma motoneuron circuitry: a neglected mechanism for understanding myofascial pain syndromes?. Appl Psychophysiol Biofeedback 23 (1998) 43-57
17. Dundar U., Evcik D., Samli F., Pusak H., and Kavuncu V. The effect of gallium arsenide aluminum laser therapy in the management of cervical myofascial pain syndrome: a double blind, placebo-controlled study. Clin Rheumatol 26 (2007) 930-934
18. Durette M.R., Rodriquez A.A., Agre J.C., and Silverman J.L. Needle electromyographic evaluation of patients with myofascial or fibromyalgic pain. Am J Phys Med Rehabil 70 (1991) 154-156
19. Edwards J. The importance of postural habits in perpetuating myofascial trigger point pain. Acupunct Med 23 (2005) 77-82
20. Esenyel M., Caglar N., and Aldemir T. Treatment of myofascial pain. Am J Phys Med Rehabil 79 (2000) 48-52
21. Evaskus D.S., and Laskin D.M. A biochemical measure of stress in patients with myofascial pain-dysfunction syndrome. J Dent Res 51 (1972) 1464-1466
22. Farber L., Haus U., Spath M., and Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl 119 (2004) 2-8
23. Farina S., Casarotto M., Benelle M., Tinazzi M., Fiaschi A., Goldoni M., and Smania N. A randomized controlled study on the effect of two different treatments (FREMS AND TENS) in myofascial pain syndrome. Eura Medicophys 40 (2004) 293-301
24. Filippi G.M., Errico P., Santarelli R., Bagolini B., and Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113 (1993) 400-404
25. Finley JE. Myofascial Pain. Physical Medicine and Rehabilitation. 2006. [electronic link: www.eMedicine.com, accessed Dec 3, 2006].
26. Fishbain D.A., Cutler R.B., Rosomoff H.L., and Rosomoff R.S. Clonazepam open clinical treatment trial for myofascial syndrome associated chronic pain. Pain Med 1 (2000) 332-339
27. Forst R., and Ingenhorst A. Myofascial pain syndrome [in German]. Internist (Berl) 46 (2005) 1207-1217
28. Freund B.J., and Schwartz M. Treatment of whiplash associated neck pain with botulinum toxin-A: a pilot study. J Rheumatol 27 (2000) 481-484
29. Fricton J.R. Masticatory myofascial pain: an explanatory model integrating clinical, epidemiological and basic science research. Bull Group Int Rech Sci Stomatol Odontol 41 (1999) 14-25
30. Fricton J.R. Myofascial pain syndrome. Neurol Clin 7 (1989) 413-427
31. Gam A.N., Warming S., Larsen L.H., Jensen B., Hoydalsmo O., Allon I., Andersen B., Gotzsche N.E., Petersen M., and Mathiesen B. Treatment of myofascial trigger-points with ultrasound combined with massage and exercise-a randomised controlled trial. Pain 77 (1998) 73-79
32. Gavish A., Winocur E., Astandzelov-Nachmias T., and Gazit E. Effect of controlled masticatory exercise on pain and muscle performance in myofascial pain patients: A pilot study. Cranio 24 (2006) 184-190
33. Gerwin R.D. A review of myofascial pain and fibromyalgia--factors that promote their persistence. Acupunct Med 23 (2005) 121-134
34. Gessa G.L., Casu M.A., Carta G., and Mascia M.S. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus. Eur J Pharmacol 355 (1998) 119-124
35. Glaros A.G., Williams K., and Lausten L. The role of parafunctions, emotions and stress in predicting facial pain. J Am Dent Assoc 136 (2005) 451-458
36. Glyn J.H. Rheumatic pains: Some concepts and hypotheses. Proc R Soc Med 64 (1971) 354-360
37. Goddard G. Short term pain reduction with acupuncture treatment for chronic orofacial pain patients. Med Sci Monit 11 (2005) CR71-CR74
38. Goldstein L.B., Last F.C., and Salerno V.M. Prevalence of hyperactive digastric muscles during swallowing as measured by electromyography in patients with myofascial pain dysfunction syndrome. Funct Orthod 14 (1997) 18-22 24
39. Graboski C.L., Gray D.S., and Burnham R.S. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 118 (2005) 170-175
40. Graff-Radford S.B. Myofascial pain: diagnosis and management. Curr Pain Headache Rep 8 (2004) 463-467
41. Gunn C.C., and Milbrandt W.E. Tenderness at motor points: an aid in the diagnosis of pain in the shoulder referred from the cervical spine. J Am Osteopath Assoc 77 (1977) 196-212
42. Gur A., Sarac A.J., Cevik R., Altindag O., and Sarac S. Efficacy of 904 nm gallium arsenide low level laser therapy in the management of chronic myofascial pain in the neck: a double-blind and randomize-controlled trial. Lasers Surg Med 35 (2004) 229-235
43. Heiberg A., Heloe B., Heiberg A.N., Heloe L.A., Magnus P., Berg K., and Nance W.E. Myofascial pain dysfunction (MPD) syndrome in twins. Community Dent Oral Epidemiol 8 (1980) 434-436
44. Hohmann A.G., and Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92 (1999) 1171-1175
45. Hong C.Z. Pathophysiology of myofascial trigger point. J Formos Med Assoc 95 (1996) 93-104
46. Hopwood M.B., and Abram S.E. Factors associated with failure of trigger point injections. Clin J Pain 10 (1994) 227-234
47. Ibraham G.A., Awad E.A., and Kottke F.J. Interstitial myofibrositis: Serum and muscle enzymes and lactate dehydrogenase-isoenzymes. Arch Phys Med Rehabil 35 (1974) 23-28
48. Ilbuldu E., Cakmak A., Disci R., and Aydin R. Comparison of laser, dry needling, and placebo laser treatments in myofascial pain syndrome. Photomed Laser Surg 22 (2004) 306-311
49. Jankovic J., and Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 40 (1990) 277-280
50. Kamanli A., Kaya A., Ardicoglu O., Ozgocmen S., Zengin F.O., and Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 25 (2005) 604-611
51. Kapel L., Glaros A.G., and McGlynn F.D. Psychophysiological responses to stress in patients with myofascial pain-dysfunction syndrome. J Behav Med 12 (1989) 397-406
52. Kitagawa Y., Enomoto S., Nakamura Y., and Hashimoto K. Asymmetry in jaw-jerk reflex latency in craniomandibular dysfunction patients with unilateral masseter pain. J Oral Rehabil 27 (2000) 902-910
53. Kitami K. Interrelation between physical disease and chronic pain--importance of understanding myofascial pain syndrome [in Japanese/Abstract]. Nippon Rinsho 59 (2001) 1768-1772
54. Kuan T.S., Chen J.T., Chen S.M., Chien C.H., and Hong C.Z. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil 81 (2002) 512-520 quiz 521-3
55. Lang A.M. A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: a retrospective, open-label chart review. Clin Ther 25 (2003) 2268-2278
56. Lester H.A., and Karshin A. Gain of function mutants: ion channels and G protein-coupled receptors. Annu Rev Neurosci 23 (2000) 89-125
57. Lewis J., and Tehan P. A blinded pilot study investigating the use of diagnostic ultrasound for detecting active myofascial trigger points. Pain 79 (1999) 39-44
58. Losavio A., and Muchnik S. Spontaneous acetylcholine release in mammalian neuromuscular junctions. Am J Physiol 273 (1997) C1835-C1841
59. Lund N., Bengtsson A., and Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 15 (1986) 165-173
60. Majlesi J., and Unalan H. High-power pain threshold ultrasound technique in the treatment of active myofascial trigger points: a randomized, double-blind, case-control study. Arch Phys Med Rehabil 85 (2004) 833-836
61. Malanga G.A., Gwynn M.W., Smith R., and Miller D. Tizanidine is effective in the treatment of myofascial pain syndrome. Pain Physician 5 (2002) 422-432
62. Manfredini D., Romagnoli M., Cantini E., and Bosco M. Efficacy of tizanidine hydrochloride in the treatment of myofascial face pain. Minerva Med 95 (2004) 165-171
63. McPartland J.M. Travell trigger points - molecular and osteopathic perspectives. J Am Osteopath Assoc 104 (2004) 244-249
64. Mense S. Considerations concerning the neurobiological basis of muscle pain. Can J Physiol Pharmacol 69 (1991) 610-616
65. Mense S., and Simons D.G. Muscle Pain: Understanding its Nature, Diagnosis, and Treatment (2001), Lippincott Williams & Wilkins, Philadelphia
66. Miehlke K, Schulz G, Eger W. Clinical and experimental studies on the fibrositis syndrome. Z Rheumaforsch 19:310-330, 1960. [Quoted in: Fricton JR. Myofascial pain syndrome. Neurol Clin 7:413-27, 1989].
67. Mills K.R., Newham D.J., and Edwards R.H.T. Muscle pain. In: Wall P.D., and Melzack R. (Eds). Textbook of Pain. 2nd edn. (1989), Churchill Livingstone, Edinburgh 420-432
68. Moldofsky H., Scarisbrick P., England R., and Smythe H. Myoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 37 (1975) 341-351
69. Muller W., Fiebich B.L., and Stratz T. New treatment options using 5-HT3 receptor antagonists in rheumatic diseases. Curr Top Med Chem 6 (2006) 2035-2042
70. Muller W., and Stratz T. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron. Scand J Rheumatol Suppl 119 (2004) 44-48
71. Nadler S.F., Feinberg J.H., Reisman S., Stitik T.P., DePrince M.L., Hengehold D., and Weingand K. Effect of topical heat on electromyographic power density spectrum in subjects with myofascial pain and normal controls: a pilot study. Am J Phys Med Rehabil 80 (2001) 809-815
72. Ohno K., and Engel A.G. Congenital myasthenic syndromes: genetic defects of the neuromuscular junction. Curr Neurol Neurosci Rep 2 (2002) 78-88
73. Ojala T., Arokoski J.P., and Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 22 (2006) 90-96
74. Orlando B., Manfredini D., and Bosco M. Efficacy of physical therapy in the treatment of masticatory myofascial pain: a literature review. Minerva Stomatol 55 (2006) 355-366
75. Pearce J.M. Myofascial pain, fibromyalgia or fibrositis?. Eur Neurol 52 (2004) 67-72
76. Pellegrino M.J., Waylonis G.W., and Sommer A. Familiar occurrence of primary fibromyalgia. Arch Phys Med Rehabil 70 (1989) 61-63
77. Pettengill C.A., and Reisner-Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. Cranio 15 (1997) 53-56
78. Pogrel M.A., McNeill C., and Kim J.M. The assessment of trapezius muscle symptoms of patients with temporomandibular disorders by the use of liquid crystal thermography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82 (1996) 145-151
79. Qerama E., Fuglsang-Frederiksen A., Kasch H., Bach F.W., and Jensen T.S. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 67 (2006) 241-245
80. Rivner M.H. The neurophysiology of myofascial pain syndrome. Curr Pain Headache Rep 5 (2001) 432-440
81. Rosales R.L., Arimura K., Takenaga S., and Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19 (1996) 488-496
82. Saxen M.A. Myofascial pain syndrome: characteristics, diagnosis, and treatment. J Indiana Dent Assoc 77 (1998) 9-12
83. Seltzer S, Dewart D, Pollack RL, Jackson E. The effects of dietary tryptophan on chronic maxillofacial pain and experimental pain tolerance. J Psychiatr Res 1982-83: 17: 181-6.
84. Simons D.G. Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. J Electromyogr Kinesiol 14 (2004) 95-107
85. Simons D.G., Hong C.Z., and Simons L.S. Endplate potentials are common to midfiber myofacial trigger points. Am J Phys Med Rehabil 81 (2002) 212-222
86. Simons D.G., and Mense S. Diagnosis and therapy of myofascial trigger points [in German]. Schmerz 17 (2003) 419-424
87. Simons D.G., Travell J.G., and Simons L.S. Travell and Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual: Upper Half of Body. 2nd edn. 1 (1999), Williams & Wilkins, Baltimore
88. Smania N., Corato E., Fiaschi A., Pietropoli P., Aglioti S.M., and Tinazzi M. Repetitive magnetic stimulation: a novel therapeutic approach for myofascial pain syndrome. J Neurol 252 (2005) 307-314
89. Smith H., and Elliot J. Alpha2 receptors and agonists in pain management. Curr Opin Anaesthesiol 14 (2001) 513-518
90. Smith P., Mosscrop D., Davies S., Sloan P., and Al-Ani Z. The efficacy of acupuncture in the treatment of temporomandibular joint myofascial pain: a randomised controlled trial. J Dent 35 (2007) 259-267
91. Stratz T., and Muller W. Local treatment of rheumatic diseases with the 5-HT3 receptor antagonist tropisetron [in German]. Schmerz 17 (2003) 200-203
92. Swerdlow B., and Dieter J.N. An evaluation of the sensitivity and specificity of medical thermography for the documentation of myofascial trigger points. Pain 48 (1992) 205-213
93. Thant Z.S., and Tan E.K. Emerging therapeutic applications of botulinum toxin. Med Sci Monit 9 (2003) RA40-RA48
94. Thornhill M.H. Masticatory muscle symptoms in a patient with McArdle's disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81 (1996) 544-546
95. Travell J.G., and Simons D.G. Myofascial Pain and Dysfunction: The Trigger Point Manual: The Upper Extremities 1 (1983), Williams & Wilkins, Baltimore
96. Tschopp K.P., and Gysin C. Local injection therapy in 107 patients with myofascial pain syndrome of the head and neck. ORL J Otorhinolaryngol Relat Spec 58 (1996) 306-310
97. Velly A.M., Gornitsky M., and Philippe P. Contributing factors to chronic myofascial pain: a case-control study. Pain 104 (2003) 491-499
98. Wheeler A.H. Myofascial pain disorders: theory to therapy. Drugs 64 (2004) 45-62
99. Wheeler A.H., and Goolkasian P. Open label assessment of botulinum toxin A for pain treatment in a private outpatient setting. J Musculoskeletal Pain 9 (2001) 67-82
100. Wheeler A.H., Goolkasian P., and Gretz S.S. Botulinum toxin A for the treatment of chronic neck pain. Pain 94 (2001) 255-260
101. Wiegand H., and Wellhoner H.H. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 298 (1977) 235-238
102. Wigers S.H., and Finset A. Rehabilitation of chronic myofascial pain disorders [in Norwegian/Abstract]. Tidsskr Nor Laegeforen 127 (2007) 604-608
103. Wissel J., Muller J., Dressnandt J., Heinen F., Naumann M., Topka H., and Poewe W. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20 (2000) 44-49
104. Wolfe F., Simons D.G., Fricton J., Bennett R.M., Goldenberg D.L., Gerwin R., Hathaway D., McCain G.A., Russell I.J., Sanders H.O., et al. The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J Rheumatol 19 (1992) 944-951
105. Yap E.C. Myofascial pain--an overview. Ann Acad Med Singapore 36 (2007) 43-48
106. Yunus M.B., Kalyan-Raman U., Kalyan-Raman K., and Masi A.T. Pathologic changes in muscle in primary fibromyalgia syndrome. Am J Med 81 (1986) 38-42